MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $2.09 Million Position in The Clorox Company (NYSE:CLX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in The Clorox Company (NYSE:CLX - Free Report) by 19.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,866 shares of the company's stock after selling 3,091 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Clorox were worth $2,090,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CLX. Norges Bank acquired a new position in shares of Clorox in the fourth quarter valued at approximately $259,041,000. FMR LLC boosted its holdings in shares of Clorox by 75.4% in the fourth quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after buying an additional 585,526 shares during the period. Marshall Wace LLP boosted its holdings in shares of Clorox by 549.8% in the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock valued at $88,144,000 after buying an additional 459,203 shares during the period. ExodusPoint Capital Management LP boosted its holdings in shares of Clorox by 187.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock valued at $113,508,000 after buying an additional 456,114 shares during the period. Finally, Balyasny Asset Management L.P. boosted its holdings in shares of Clorox by 28.7% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,421,909 shares of the company's stock valued at $230,932,000 after buying an additional 316,688 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Insider Buying and Selling at Clorox

In related news, Director Pierre R. Breber acquired 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.57% of the company's stock.

Analyst Ratings Changes

CLX has been the topic of a number of research reports. Barclays cut their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley cut their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. UBS Group cut their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Evercore ISI set a $140.00 price objective on shares of Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. Finally, Citigroup cut their price objective on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research report on Monday, April 14th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $151.23.

Clorox Stock Performance

NYSE CLX traded down $0.58 on Tuesday, hitting $130.30. 2,190,099 shares of the stock were exchanged, compared to its average volume of 1,337,367. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The business's fifty day moving average is $139.05 and its 200 day moving average is $151.85. The Clorox Company has a 52 week low of $127.60 and a 52 week high of $171.37. The company has a market capitalization of $16.06 billion, a PE ratio of 35.60, a P/E/G ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same period last year, the company posted $1.71 earnings per share. The business's revenue was down 8.0% compared to the same quarter last year. Research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.